Aachen, 08 July 2026 – Grünenthal, a global leader in pain management and related diseases, announced today that their investigational compound tegacorat (GRM-01) has received Orphan Drug and Rare Pediatric Disease Designations from the US Food and Drug Administration (FDA) for the treatment of Duchenne muscular dystrophy (DMD).
Tegacorat, a non-steroidal Selective Glucocorticoid Receptor Agonist and Modulator (SEGRAM), is an orally available investigational compound that aims to provide a viable alternative to glucocorticoid-based treatments, such as prednisone, which is currently the standard of care for DMD.
According to Uli Brödl, Chief Scientific Officer at Grünenthal, “With the current standard of care, people affected by DMD, their caregivers and clinicians must constantly balance efficacy and the burden of side effects as they pursue the essential goal of preserving muscle function.” Tegacorat is being developed to address this unmet need by providing a long-term therapy option with potent anti-inflammatory efficacy while also reducing dose- and duration-dependent side effects.
The Orphan Drug and Rare Pediatric Disease designations mark a significant milestone in the development of tegacorat. Grünenthal is now preparing for a Phase II trial to further investigate the efficacy, safety, and tolerability of tegacorat in DMD. The trial is expected to commence later in 2026 at centers in the US and Europe.
Duchenne muscular dystrophy is a rare genetic disorder affecting around 1 in every 5,000 boys born. It is caused by mutations in the dystrophin gene, which leads to progressive muscle weakness throughout the body, affecting mobility, breathing, and the heart. DMD is currently incurable and results in death, usually between 21 and 40 years of age.
The current treatment options for DMD are not curative nor preventive of disease progression. While glucocorticoids are the standard of care, they come with significant side effects, including cushingoid appearance, weight gain, and behavioral changes.
Grünenthal, headquartered in Aachen, Germany, is a science-based, fully integrated pharmaceutical company with a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Their purpose is to change lives for the better, and their passion is innovation. Currently, Grünenthal has affiliates in 28 countries across Europe, Latin America, and the U.S., and their products are available in approximately 100 countries. In 2025, they employed around 4,100 people and achieved revenues of €1.8 billion.
For further information, please contact Christopher Jansen, Global Communications at Grünenthal, at christopher.jansen@grunenthal.com.
References:
– Crisafulli S, et al. Global epidemiology of Duchenne muscular dystrophy: an updated systematic review and meta-analysis. Orphanet J Rare Dis. 2020; 15(1):141.
– Bez Batti Angulski A, et al. Duchenne muscular dystrophy: disease mechanism and therapeutic strategies. Front Physiol. 2023; 14:1183101.
– Landfeldt E, et al. Life expectancy at birth in Duchenne muscular dystrophy: a systematic review and meta-analysis. Eur J Epidemiol. 2020; 35(7):643-653. [Estimated mortality for those who receive ventilatory support.]
– Fischer R, et al. A Mixed-Method Study Exploring Patient-Experienced and Caregiver-Reported Benefits and Side Effects of Corticosteroid Use in Duchenne Muscular Dystrophy. J Neuromuscul Dis. 2023;10(4):593-613.
